AHA GUIDELINES Bundle (free trial)

ST-Elevation Myocardial Infarction

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/104088

Contents of this Issue

Navigation

Page 5 of 29

Treatment Aspiration Thrombectomy ÎÎManual aspiration thrombectomy is reasonable for patients undergoing primary PCI. (IIa-B) Use of Stents in Primary PCI ÎÎPlacement of a stent (bare-metal stent [BMS] or drug-eluting stent [DES]) is useful in primary PCI for patients with STEMI. (I-A) ÎÎBMSa should be used in patients with high bleeding risk, inability to comply with 1 year of dual antiplatelet therapy (DAPT), or anticipated invasive or surgical procedures in the next year. (I-C) ÎÎDES should NOT be used in primary PCI for patients with STEMI who are unable to tolerate or comply with a prolonged course of DAPT because of the increased risk of stent thrombosis with premature discontinuation of one or both agents. (III-B: Harm) a Balloon angioplasty without stent placement may be used in selected patients. Adjunctive Antithrombotic Therapy for Primary PCI (Table 3) Antiplatelet Therapy ÎÎAspirin 162-325 mg should be given before primary PCI. (I-B) ÎÎAfter PCI, aspirin should be continued indefinitely. (I-A) ÎÎA loading dose of a P2Y12 receptor inhibitor should be given as early as possible or at the time of primary PCI to patients with STEMI. Options include: •  Clopidogrel 600 mg (I-B) or •  Prasugrel 60 mg (I-B) or •  Ticagrelor 180 mg (I-B) ÎÎP2Y12 inhibitor therapy should be given for 1 year to patients with STEMI who receive a stent (BMS or DES) during primary PCI using the following maintenance doses: a •  Clopidogrel 75 mg daily (I-B) or •  Prasugrel 10 mg daily (I-B) or •  Ticagrelor 90 mg bida (I-B) The recommended maintenance dose of aspirin to be used with ticagrelor is 81 mg daily. ÎÎIt is reasonable to use 81 mg of aspirin per day in preference to higher maintenance doses after primary PCI. (IIa-B) ÎÎIt is reasonable to begin treatment with an intravenous GP IIb/ IIIa receptor antagonist such as abciximab (IIa-A), high-bolus-dose tirofiban (IIa-B), or double-bolus eptifibatide (IIa-B) at the time of primary PCI (with or without stenting or clopidogrel pretreatment) in selected patients with STEMI who are receiving unfractionated heparin (UFH). 4

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - ST-Elevation Myocardial Infarction